SCK CEN’s Post

🎗️⚛️ #EANM 2025 – Take-away #2 Understanding radiopharmaceutical behaviour in the body just got sharper thanks to Justine’s newly developed PBPK* model, presented at #EANM2025. 💬 “We integrated preclinical biodistribution data into a PBPK* modeling framework. This model confirmed that [161Tb]Tb-DOTA-TATE and [177Lu]Lu-DOTA-TATE share a similar pharmacokinetic profile. It also shows strong potential for generalization across DOTA-TATE–based radiopharmaceuticals, successfully extending to ⁶⁸Ga and others”, says Justine Henriot. *PBPK: physiologically-based pharmacokinetic 🚀 These insights guide radiopharmaceutical development and brings us closer to personalized cancer care. Many thanks to the co-authors who helped shape these findings: Lara Struelens, Michelle Andersson, Sunay Rodriguez Pérez, Michel Koole, and Clarita Saldarriaga Vargas. #radioligandtherapy #radiopharmaceuticals #dosimetry #PBPK - European Association of Nuclear Medicine (EANM)

Results from the IPAX-Linz trial of Telix’s glioma (brain cancer) therapeutic candidate, TLX101 ([¹³¹I]IPA), will be presented at EANM by Principal Investigator Prof. Josef Pichler, Kepler University Hospital. This investigator-initiated study evaluated TLX101 in combination with second-line external beam radiation therapy, the current standard of care in recurrent glioblastoma (GBM). The study showed a favorable safety and tolerability profile, with no serious adverse events. Importantly, encouraging signals of efficacy were observed, even in patients with MGMT unmethylated tumors, typically associated with especially poor prognosis. These findings support the ongoing development of TLX101, which is now advancing into the Phase 3 IPAX-BrIGHT trial. Watch Dr Pichler explain more about the purpose of the IPAX series of studies and the critical need for new therapeutic options in treating GBM. Learn more about Telix’s presence at EANM here: https://lnkd.in/gV4abiRb TLX101 has not received a marketing authorization in any jurisdiction. European Association of Nuclear Medicine (EANM) #EANM25

🔬 On the occasion of the European Association of Nuclear Medicine (EANM) Congress, EORTC is proud to highlight its leadership in Radioligand Therapy (RLT) and nuclear medicine. Through its Radioligand Task Force, EORTC is working to generate the clinical evidence needed to support the use of radioligands in oncology. Key highlights on EORTC studies:  ✅ LUMEN-1: A phase II trial evaluating [177Lu]Lu-DOTATATE in patients with recurrent meningioma.  ✅ RENALUT: Investigating [177Lu]Lu-PSMA-617 in metastatic renal cell carcinoma  ✅ PEACE III: A landmark trial using radium-223 in combination with enzalutamide for prostate cancer with bone metastases These studies are part of a broader effort to make cancer treatment more precise, effective, and accessible across Europe. 👉 Read our full article here: https://lnkd.in/dZ6Js725 #EANM2025 #EORTC #RadioligandTherapy #CancerResearch #Theranostics #ClinicalTrials 

🎗️🧬 #EANM 2025 – Take-away #1 During her presentation, Sara Van Mechelen showcased the added value of dimeric compounds in FAP-targeted radioligand therapy for ovarian cancer. FAP targeting is a promising strategy in ovarian cancer, but current monomeric compounds like FAPI-46 suffer from limited tumor retention. Dimeric compounds have two binding sites, allowing them to overcome this limitation. 🧲 Think of it as using two magnets instead of one for a firmer grip. 💬 “Within the Innovative Health Initiative project Thera4Care, we demonstrate that the dimeric radioligand [¹⁶¹Tb]Tb-DOTAGA.Glu.(FAPI)₂ can achieve significantly stronger tumor-specific binding in ovarian cancer models. Combined with the emission properties of terbium-161, this next-generation radioligand holds game-changing potential to strengthen radiotheranostic strategies for ovarian cancer and other FAP-positive tumors”, explains Sara Van Mechelen. #radioligandtherapy #radiopharmaceuticals #ovariancancer #Thera4Care #innovation - European Association of Nuclear Medicine (EANM)

Building a Smarter Warhead for Cancer: Connecting Nuclear Physics, Molecular Scaffolds, and Targeted Therapy A few weeks ago, I shared a post about the fascinating physics behind producing Lutetium-177, where a specific resonance peak in the neutron cross-section is the key to creating a powerful tool for prostate cancer therapy. But how do we get this potent isotope to the right place? I was incredibly inspired by a recent post from SCK CEN featuring the work of Sara Van Mechelen on Terbium-161 in ovarian cancer. They highlighted a crucial concept: dimeric FAP-targeting ligands. The takeaway is powerful – using two binding sites ("two hands") instead of one dramatically improves tumor retention and therapeutic potential. This principle of multivalent binding is a game-changer for making sure the therapy stays where it's needed. This brings us to the bridge: the delivery vehicle itself. How can we combine a powerful isotope with a multi-pronged targeting system? I came across a fascinating paper, "The large in the small: The iodination of the corrole ring" by Carofeo et al. in the Journal of Porphyrins and Phthalocyanines. At first glance, it's deep organic chemistry, but the implications are huge. They demonstrate a method to precisely place multiple iodine atoms on a corrole ring. Here’s where we connect the dots: Imagine that iodinated corrole ring not just as a molecule, but as a customizable molecular chassis. The Engine: The center of the corrole ring is a perfect spot to chelate (securely hold) a therapeutic or theranostic isotope like Lutetium-177 or the highly promising Terbium-161. The Attachment Points: The iodine atoms, as demonstrated by Carofeo et al., act as perfect "LEGO-like" connectors. Through established chemical reactions, we can replace them. The Guidance System: Instead of just one or two targeting vectors, we could use these multiple attachment points to link several targeting ligands (like PSMA for prostate cancer, or FAP for a range of tumors). This would create a "multi-valent" radiopharmaceutical, amplifying the "firmer grip" concept shared by SCK CEN. A superior, multi-point guidance system for enhanced tumor binding and retention. The path from a resonance peak in a nucleus to a multi-pronged attack on cancer cells is paved by this kind of interdisciplinary science. It’s a testament to how fundamental research in one field can unlock immense potential in another. What are your thoughts on using macrocyclic scaffolds like corroles for developing next-generation multivalent radiopharmaceuticals? #InterdisciplinaryScience #MedicalPhysics #NuclearPhysics #Radiopharmaceuticals #TargetedTherapy #Theranostics #CancerResearch #Lutetium177 #Terbium161 #OrganicChemistry #DrugDelivery #Innovation #ProstateCancer

We’re proud to support our research collaborators from the University of Wisconsin-Madison as they present new preclinical data at the European Association of Nuclear Medicine (EANM) 2025 Annual Congress in Barcelona, Spain.   Several abstracts highlight the potential of the NM600 platform across tumor types and therapeutic strategies, including studies of isotope selection and combination approaches in cancer models.   To learn more about Archeus’ NM600 platform and differentiated pipeline of radiopharmaceutical therapies, connect with Evan Sengbusch and Reinier Hernandez at #EANM25. #Radiopharmaceuticals #Oncology #Theranostics

We had an excellent EANM25 Congress in Barcelona ! Thank you to all who joined us and contributed to the rich scientific exchange. Here are some highlights from our participation at #EANM25.   This year’s discussions spotlighted how radiopharmaceuticals are redefining care for patients with mCRPC.   The opening ceremony marked the 40th anniversary of EANM, celebrating four decades of innovation in nuclear medicine 🎉   Sessions featured new data on combination approaches with radiopharmaceuticals in mCRPC.   The congress showcased the growing innovation and expanding relevance of radiopharmaceuticals—not only in prostate cancer but across emerging therapeutic areas.   Explore more in the abstracts: https://lnkd.in/gq75xHCM We look forward to continuing the dialogue at ESMO25 in Berlin! #EANM25 #ESMO25 #Oncology #TeamBayer #ProstateCancer Andreas SutterRaphaël BierlaireDominic RedmondJulio Pozueta PhD

At the European Association of Nuclear Medicine (EANM) World Leading Meeting 2025, researchers from DKFZ German Cancer Research Center presented data from the first clinical experience with an early Bicycle® Imaging Agent (BIA) targeting MT1-MMP, a protein overexpressed in various solid tumors. They also presented preclinical data for BIAs optimized for pharmacokinetics to significantly enhance tumor targeting and minimize non-specific uptake. Check out the posters here: https://bit.ly/4ab2P9c. As we look to start our own Bicycle Therapeutics-sponsored #radiopharmaceutical clinical trials next year, we are encouraged by the data as they continue to validate the potential of MT1-MMP as a novel #cancer target and position our Bicycle technology for use as potential #radiopharm therapies.

AdvanCell is excited to announce six presentations at the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM) on October 4-8, 2025, in Barcelona. The presentations span cutting-edge clinical study design and development, preclinical science, and translational research that demonstrate the promise of #212Pb as the leading platform for #RadioligandTherapies to treat cancer. In addition, AdvanCell will present the first clinical data from the Phase 1b part of the #TheraPb trial at the upcoming 2025 ESMO Congress. Read more in our press release: https://lnkd.in/eHUzQSaY #EANM25 #TeamAdvanCell #ADVC001 #TheraPb #212Pb #RLT #HeavyMetalTherapy

We are excited to announce two oral presentations at the European Association of Nuclear Medicine (EANM) congress, showcasing our novel SANTANA-225 Phase 1/2 clinical trial design and preclinical data that underscore the potential of 225Ac-SSO110 as a best-in-class alpha-emitting radioligand therapy for SSTR2-positive tumours. The data demonstrate robust tumour localization and effective Bi-213 retention in target lesions for SCLC, an aggressive cancer with dismal prognosis and significant unmet need. Title: Improved Tumour Targeting and Efficacy with Comparable Daughter Redistribution of 225Ac-SSO110 versus 225Ac-DOTA-TATE in a Preclinical SCLC Model Presentation #: OP-658 Presented by: Prachi Desai, PhD 📅 Tuesday, October 7, 2025 🕥 15:00 - 16:30 CET 📍 Room 114 Title: SANTANA-225: A multicentre, open-label, Phase I/II study investigating the safety, tolerability, and preliminary efficacy of 225Ac-SSO110 in participants with extensive stage small cell lung cancer (ES-SCLC) or Merkel cell carcinoma (MCC) receiving Standard of Care (SoC) Presentation #: OP-780 Presented by: Elcin Zan, MD 📅 Wednesday, October 8, 2025 🕥 08:00 - 09:30 CET 📍 Room 117 We are looking forward to connecting with our peers and advancing the conversation around next-generation radiotherapeutics! #EANM2025 #Radiopharmaceuticals #RadioligandTherapy #Oncology #SCLC #MCC #Biotech #Lifesciences